| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(8 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(10 years from now) | |
Dilaudid is owned by Fresenius Kabi Usa.
Dilaudid contains Hydromorphone Hydrochloride.
Dilaudid has a total of 2 drug patents out of which 0 drug patents have expired.
Dilaudid was authorised for market use on 11 January, 1984.
Dilaudid is available in injectable;injection dosage forms.
The generics of Dilaudid are possible to be released after 12 March, 2034.
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 January, 1984
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of DILAUDID before it's drug patent expiration?
More Information on Dosage
DILAUDID family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic